What Does Shock Wave Therapy Do for Tendons?

Shock wave therapy delivers high-pressure acoustic pulses into damaged tendon tissue, creating controlled microtrauma that restarts stalled healing. It triggers mechanotransduction in tenocytes, upregulates growth factors like TGF-β1 and VEGF, and promotes neovascularization to restore blood flow. The therapy also depletes substance P from nerve endings, reducing chronic pain signaling. It’s most effective for tendons that haven’t responded to conventional treatments, particularly when combined with structured rehabilitation. The mechanisms behind each stage of recovery reveal why protocol details matter.

Key Takeaways

Shockwave therapy stimulates tenocytes through mechanotransduction, triggering growth factor cascades that promote collagen synthesis and extracellular matrix remodeling.
It induces neovascularization via VEGF and eNOS upregulation, restoring oxygen and nutrient delivery to damaged tendon tissue.
Controlled cavitation-induced microtrauma removes degenerated matrix and resets chronic tendon biology from degeneration toward organized healing.
It depletes substance P and CGRP from nerve endings, reducing neurogenic inflammation and breaking chronic pain sensitization loops.
Dose parameters like energy flux density determine therapeutic effectiveness, with low-to-medium levels stimulating repair without causing structural damage.

How Shock Wave Therapy Triggers Tendon Healing

Shock wave therapy for tendons delivers focused acoustic waves that activate a cascade of biological repair mechanisms in damaged tissue. These acoustic pulses stimulate neovascularization, cell proliferation, collagen synthesis, and extracellular matrix remodeling—processes that reinitiate stalled healing in chronic tendinopathy.

The mechanical energy from shock waves acts as a mechanotransductive stimulus, converting acoustic force into biochemical signals within tenocytes and fibroblasts. This activation upregulates key growth factors, including VEGF, TGF-β, and IGF-1, which drive vascular ingrowth and matrix production. Cavitation-induced microdamage further enhances local perfusion and triggers a controlled inflammatory response that clears degenerated tissue. In cases of calcific tendinopathy, shock waves also physically disrupt calcium deposits in tendons, allowing the body to reabsorb them and restore healthier tissue architecture.

Over subsequent weeks, these coordinated biological processes progressively restore tendon structure, improve tensile strength, and enhance biomechanical resistance to stress.

Why Chronic Tendons Get Stuck: and How Shock Waves Help

When tendons enter a degenerative state marked by collagen disarray, angiofibroblastic hyperplasia, and impaired matrix turnover, they lose the capacity to mount an effective healing response despite continued conservative care. This failed repair cycle sustains elevated nociceptive signaling—driven by substance P upregulation, abnormal nerve ingrowth, and central sensitization—that further reduces load tolerance and perpetuates structural decline.

Extracorporeal shock wave therapy addresses both problems simultaneously by reactivating biological repair mechanisms in degraded tissue while disrupting the entrenched pain pathways that keep patients trapped in dysfunction. Part of this analgesic effect operates through hyperstimulation of sensory input in small nerve fibers, which increases central biasing mechanism activity and effectively closes the gate to ongoing peripheral pain signals. By promoting new blood vessel formation and collagen production, shock wave therapy helps restore the circulatory environment that chronically degenerated tendons require to finally advance through the body’s natural rebuilding and remodeling phases.

Chronic Tendon Healing Failure

Although acute tendon injuries typically progress through overlapping phases of inflammation, proliferation, and remodeling, chronic tendinopathy represents a fundamentally different biological state—one in which the healing response has stalled.

Rather than resolving, the tendon remains trapped in a degenerative cycle characterized by disorganized extracellular matrix, collagen disarray, and increased ground substance—without the classic acute inflammatory infiltrate needed to drive repair forward.

Reduced matrix metalloproteinase activity, particularly MMP-9, limits the removal of damaged tissue, allowing microdamage and non-functional matrix components to accumulate.

Tenocytes adopt altered phenotypes, showing rounding and clustering rather than normal elongated morphology.

Growth factor signaling becomes dysregulated, creating persistent imbalance between matrix synthesis and degradation.

This failed healing environment explains why chronic tendinopathy responds poorly to rest and conventional anti-inflammatory treatments—the problem isn’t active inflammation but biological stagnation.

Reactivating The Repair Process

Because chronic tendinopathy reflects biological stagnation rather than active inflammation, effective treatment must restart the repair process at the cellular level—and this is precisely where extracorporeal shock wave therapy (ESWT) exerts its primary therapeutic effect. ESWT delivers high-pressure acoustic pulses that deform tendon cells and matrix, triggering mechanotransduction cascades that convert mechanical energy into biochemical repair signals.

ESWT reactivates stalled healing through three key biological mechanisms:

Growth factor upregulation — ESWT increases TGF-β1 and IGF-1 expression, driving tendon cell proliferation and matrix synthesis while upregulating the tendon-specific transcription factor scleraxis.
Inflammatory rebalancing — It downregulates catabolic interleukins and matrix metalloproteinases while promoting anti-inflammatory cytokines like IL-10.
Neovascularization — ESWT stimulates VEGF and eNOS expression, generating new capillary networks that restore oxygen and nutrient delivery to degenerative tissue.

Breaking The Pain Cycle

Beyond its effects on tissue remodeling, ESWT directly targets the neurological mechanisms that trap chronic tendons in a self-reinforcing pain loop. Chronic tendinopathy maintains pain through peripheral sensitization, aberrant neurovascular sprouting, and elevated neuropeptides like substance P and calcitonin gene-related peptide in dorsal root ganglia. Shock waves disrupt this cycle through multiple convergent pathways.

First, they activate hyperstimulation analgesia, engaging gate-control mechanisms at the spinal cord that reduce ascending nociceptive transmission. Second, repeated exposure depletes substance P from treated tissues, producing sustained analgesic effects similar to capsaicin-induced neuropeptide depletion. Third, shock waves suppress pro-inflammatory mediators and matrix metalloproteinases that sensitize local nociceptors. These combined neurochemical, anti-inflammatory, and neuromodulatory effects weaken both peripheral and central sensitization, breaking the chronic pain loop that standard loading strategies alone can’t resolve.

The Controlled Microtrauma Behind Shock Wave Therapy

Shock waves deliver high-pressure, short-duration acoustic pulses that release energy at tissue interfaces with differing acoustic impedance, generating compressive and shear loads within the tendon matrix. Cavitation bubbles form in interstitial fluid, collapse rapidly, and produce localized mechanical microtrauma that activates mechanotransduction pathways in tenocytes.

Shock waves create controlled microtrauma that awakens the tendon’s own mechanotransduction machinery, reigniting repair from within.

This controlled micro-injury triggers three critical biological responses:

Acute inflammatory cell recruitment clears damaged, degenerative matrix constituents from chronically failed tissue.
Catabolic processes eliminate abnormal collagen, mucoid deposits, and fibrotic material that perpetuate tendinopathy.
Biological resetting shifts tendon biology from chronic degeneration toward an organized, active healing phase.

Shock wave parameters—energy flux density, impulse number, and application type—determine whether microtrauma remains within a therapeutic window or crosses into overt tissue injury. Dose-dependent precision separates healing from harm. When integrated into a broader orthopedic physical therapy plan, shock wave therapy can complement manual techniques and guided exercise to restore function and address the underlying causes of tendon dysfunction.

How Shock Waves Grow New Blood Vessels at the Injury Site

When shock wave pulses strike tendon tissue, the rapid pressure gradients deform both the extracellular matrix and vascular endothelium, activating mechanotransduction pathways that drive angiogenic signaling. This mechanical stimulation upregulates endothelial nitric oxide synthase (eNOS), nitric oxide, vascular endothelial growth factor (VEGF), and proliferating cell nuclear antigen (PCNA), initiating a growth-factor cascade essential for vessel formation.

These molecular signals translate into structural changes. Histologic analyses confirm extensive capillary ingrowth from peritendinous structures into damaged tendon tissue, with increased neovessel counts at the tendon-bone junction. In human rotator cuff tendinopathy, ESWT increases vascular volume area and nodular neo-angiogenesis within deeper tendon layers.

Focused ESWT achieves deeper tissue penetration than radial approaches, making it particularly effective for neovascularization at tendon-bone interfaces. This improved local blood supply supports subsequent tissue regeneration and healing. Complementary modalities such as StimPod NMS460 further support this process by enhancing blood flow and reducing inflammation in damaged nerve and connective tissue through pulsed radiofrequency stimulation.

How Shock Waves Reset Pain Signals in Chronic Tendons

Although ESWT’s tissue-remodeling effects explain part of its clinical benefit, growing evidence points to direct modulation of pain signaling as a distinct and critical mechanism in chronic tendinopathy. Shock waves don’t just heal tissue—they recalibrate how the nervous system processes pain.

Research identifies three primary neurological mechanisms:

Neuropeptide depletion — ESWT triggers rapid release and subsequent exhaustion of substance P and CGRP from sensory nerve endings, reducing neurogenic inflammation and peripheral sensitization at the tendon.
Nociceptor desensitization — Repeated mechanical pulses selectively silence small C-fibers that carry chronic pain signals, lowering the sustained afferent barrage driving central sensitization.
Hyperstimulation analgesia — Intense acoustic input temporarily saturates spinal dorsal horn neurons, activating inhibitory circuits that outlast treatment and dampen ongoing pain transmission.

These combined effects functionally reset aberrant chronic pain circuits. Similarly, dry needling achieves comparable neurophysiological pain modulation by targeting myofascial trigger points in hyperirritable muscle bands, reducing pain perception at both the peripheral and central nervous system levels.

Why the Right Shock Wave Dose Makes a Difference

Getting the dose right determines whether shock wave therapy heals a tendon or harms it. Clinicians measure dose using energy flux density (EFD), expressed in mJ/mm². Research shows that low-to-medium EFD (0.06–0.25 mJ/mm²) stimulates tendon repair without structural damage, while levels above 0.28 mJ/mm² increase injury risk.

Factor	Low-Medium EFD (≤0.28 mJ/mm²)	High EFD (>0.28 mJ/mm²)
Tissue Safety	No reported tendon damage	Tendon lesions observed experimentally
Anaesthesia	Often unnecessary	Frequently required
Pain Relief	Comparable clinical outcomes	No proven superiority
Recovery Profile	Favorable biological response	Greater mechanical tissue stress

Meta-analyses confirm a therapeutic plateau exists—once practitioners reach a minimal effective dose, increasing energy doesn’t improve outcomes. Mid-range protocols deliver effective symptom relief while maintaining tissue safety.

Focused vs. Radial Shock Waves: Which Works Better?

Focused ESWT has demonstrated strong success rates across multiple tendinopathy types, particularly in noncalcific rotator cuff tendinopathy, where it’s produced markedly greater long-term improvements in pain and function compared to radial therapy at 24–48 weeks of follow-up.

However, evidence gaps remain substantial for radial ESWT, with limited high-quality trials available and low to very low certainty of evidence when comparing the two modalities across upper limb tendinopathies. These gaps make it difficult for clinicians to draw definitive conclusions about radial ESWT’s relative efficacy, even though individual studies in conditions like proximal hamstring tendinopathy suggest it can outperform conservative treatment. One notable exception is that RSWT significantly improved wrist extensor strength in tennis elbow compared to FSWT, supported by moderate-quality evidence with no heterogeneity between studies.

Focused ESWT Success Rates

When clinicians compare focused and radial shock wave therapy head-to-head, the evidence doesn’t crown a clear overall winner—but it does reveal meaningful differences in specific clinical scenarios.

Research shows focused ESWT delivers superior outcomes in several key areas:

Noncalcific rotator cuff tendinopathy — Focused therapy achieves NRS pain scores of 1.4±1.0 versus 3.0±0.8 for radial therapy at 48 weeks (p<0.001), demonstrating substantially greater sustained relief.
Shoulder calcific tendinitis — Focused shock waves produce statistically higher success rates due to deeper energy concentration at the calcific deposit.
Recalcitrant plantar fasciitis — Focused ESWT shows a statistically significant, though small, superiority over radial therapy in stubborn heel pain cases.

These advantages stem from focused therapy’s deeper tissue penetration, making it particularly effective for deep-seated or calcified tendon lesions. Focused ESWT achieves this by converging high-energy acoustic pulses onto a small focal zone that can reach targets up to about 12 cm below the skin, concentrating energy precisely where pathology resides while sparing overlying tissue. However, for patellar tendinopathy specifically, the TOPSHOCK trial was designed to directly compare these two modalities, using a patient and outcome assessor blinding approach to minimize bias and provide the first randomized evidence in this condition.

Radial ESWT Evidence Gaps

Despite focused therapy‘s edge in specific conditions, the broader comparative picture remains far less definitive. Systematic reviews and meta-analyses of randomized controlled trials across upper and lower limb tendinopathies have identified no clear superiority of radial over focused shock wave therapy for pain or functional outcomes. Most comparative estimates carry low or very low certainty of evidence due to small sample sizes, risk of bias, and imprecision.

Protocol heterogeneity compounds this uncertainty. Trials vary widely in energy flux density, pulse counts, frequency, and session numbers, making it difficult to attribute outcome differences to wave type versus dosing parameters. A thorough review of trials in the PEDro database concluded that no scientific evidence currently favors either modality. Radial ESWT’s evidence base requires larger, well-designed head-to-head trials before clinicians can draw definitive conclusions.

Plantar Fasciitis: Where Shock Wave Therapy Works Best

Among all tendon-related conditions, plantar fasciitis stands out as the indication where shock wave therapy has accumulated the strongest evidence. Multiple RCTs and meta-analyses confirm clinically meaningful pain reduction and functional improvement, with success rates ranging from 44% to 80%. Results prove strongest in chronic cases persisting beyond six months that haven’t responded to conservative care. As a noninvasive outpatient procedure, the treatment typically requires only local anesthesia or a sedative and can be completed in about 10–20 minutes per foot.

Three factors consistently predict the best outcomes:

Moderate-to-severe baseline pain — patients with higher initial pain scores demonstrate greater treatment response
Focused shock waves at moderate-to-high intensity — these protocols outperform low-intensity approaches for morning and activity pain
Multiple treatment sessions — typically three to five weekly sessions optimized to patient tolerance

ESWT matches or exceeds corticosteroid injections at three months and outperforms usual therapy in pooled analyses.

Does Shock Wave Therapy Help Achilles Tendinopathy?

Although plantar fasciitis claims the strongest evidence base, Achilles tendinopathy presents a more complicated picture — one where the data shift depending on the subtype treated and how ESWT fits into the broader rehab plan. Recent high-quality reviews and a 2026 meta-analysis of eight trials found no significant differences between ESWT and sham in pain or functional scores at any follow-up.

The subtype matters. A 2022 systematic review showed that adding ESWT to a tendon-loading program for mid-portion Achilles tendinopathy improved VISA-A scores by roughly 9 points — a clinically meaningful gain. Insertional cases, however, showed no benefit over standard care. When researchers evaluated ESWT as a standalone treatment, it performed no better than other conservative options. Current evidence supports ESWT only as an adjunct to structured loading programs for mid-portion disease. A 2026 randomized controlled trial (NCT07483320) is further investigating this question by comparing exercise alone versus exercise combined with ESWT, PRP, or both over six months of follow-up in active adults with midportion Achilles tendinopathy.

Why Insertional and Mid-Portion Achilles Injuries Respond Differently

Insertional and midportion Achilles tendinopathies differ fundamentally in their load environments, tissue pathology, and vascular supply, which explains why ESWT produces stronger outcomes in the midportion location—where focused energy targets a hypovascular, primarily tensile-loaded tendon body—than at the insertion, where bone–tendon interface complexity, compressive forces, and calcific co-morbidities disperse the therapeutic stimulus.

Current evidence quality reinforces this distinction: moderate-quality data support ESWT’s efficacy for midportion lesions, while very low-quality evidence shows minimal benefit over standard care for insertional disease.

These findings suggest that insertional cases likely require combined loading programs integrating eccentric–concentric exercise modifications, addressing compressive enthesis stress, and potentially pairing ESWT with targeted interventions for Haglund deformity or retrocalcaneal bursitis to achieve meaningful clinical improvement.

Insertion Versus Mid-Portion

At the Achilles tendon’s calcaneal attachment, the tissue environment differs fundamentally from the mid-portion—and these structural distinctions explain why ESWT doesn’t perform equally across both sites.

The insertional zone endures mixed tensile and compressive forces against the calcaneus, producing enthesopathy, bony spurs, and bursitis that scatter shock wave energy. The mid-portion’s chiefly tensile loading creates a more homogeneous soft-tissue medium, allowing efficient energy distribution.

Research confirms these biomechanical realities translate into measurable clinical differences:

Mid-portion ESWT produces meaningful VISA-A gains (≈9–10 points), while double-blind RCTs show no significant advantage over sham for insertional disease.
Insertional failure rates reach 59.6% at final follow-up, far exceeding mid-portion rates.
Haglund’s deformity further diminishes ESWT effectiveness in insertional cases compared to those without the deformity.

Evidence Quality Gaps

These clinical differences between insertional and mid-portion outcomes, however, rest on an evidence base riddled with methodological problems that weaken confidence in site-specific conclusions.

Case definitions vary widely—mid-portion lesions range from 2 to 6 cm above the calcaneal insertion, yet some trials include lesions outside this zone. Several RCTs pool insertional and non-insertional cases together, obscuring location-specific treatment responses.

Sample sizes remain critically small. Insertional Achilles tendinopathy trials often enroll around 50 total participants, producing wide confidence intervals and very low certainty estimates. The review identified only seven RCTs total across both tendinopathy subtypes, underscoring how thin the controlled evidence base remains for drawing definitive site-specific conclusions. The systematic review itself synthesized evidence from randomized and non-randomized controlled trials, broadening the inclusion criteria in an effort to capture enough data for meaningful analysis.

ESWT protocols compound these issues—trials use different energy flux densities, pulse counts, session frequencies, and device types (focused versus radial). Many also combine ESWT with eccentric loading or stretching, making it difficult to isolate whether anatomical location or protocol variation drives observed outcome differences.

Combined Loading Program Outcomes

When eccentric loading and low-energy shock wave therapy are combined for midportion Achilles tendinopathy, outcomes surpass those of eccentric loading alone across multiple domains. VISA-A scores climb from approximately 51 to 87, and 82% of patients report feeling “completely recovered” or “much improved” at four months.

The combined approach delivers measurable gains:

Pain drops from 7 to 2 on a 10-point scale, compared with 7 to 4 under eccentric loading alone.
Functional recovery accelerates, with superior short-term improvements in patient-reported outcomes.
Insertional cases achieve 68% success rates, though they often require adjunctive heel lifts and activity modification due to compressive loading at the enthesis.

Insertional tendinopathy responds more slowly because dorsiflexion-based eccentric protocols compress the tendon against the calcaneus, aggravating pain at the tendon–bone junction.

Combining Shock Wave Therapy With Tendon-Loading Exercises

Although shock wave therapy and tendon-loading exercises each hold standalone efficacy for chronic tendinopathies, a growing body of evidence suggests their combination yields superior outcomes. Narrative and systematic reviews consistently report that ESWT paired with eccentric training or heavy slow resistance produces greater improvements in pain and function than either intervention alone, particularly for Achilles and lateral elbow tendinopathies.

For mid-portion Achilles tendinopathy, combined ESWT and eccentric loading demonstrated notably better pain reduction and functional gains at four months, with 82% of patients reporting complete recovery or meaningful improvement. Rotator cuff tendinopathy similarly benefits from this pairing, especially when calcific deposits are present.

However, the added benefit isn’t universal. Evidence indicates ESWT provides no meaningful advantage beyond eccentric exercise alone for patellar tendinopathy.

Shock Wave Therapy vs. Cortisone Injections for Tendons

When clinicians compare shock wave therapy with cortisone injections for tendinopathies, the evidence reveals a consistent pattern: corticosteroid injections deliver faster initial pain relief, but ESWT produces equal or superior pain and functional outcomes by three to six months and beyond.

Studies report corticosteroid recurrence rates as high as 63%, while ESWT success rates range from approximately 65% to 91% with benefits sustained up to two years.

Beyond durability, ESWT promotes tendon repair through neovascularization and mechanotransduction, whereas corticosteroids can impair collagen synthesis and accelerate tendon degeneration—making ESWT the stronger long-term choice for preserving tissue integrity.

Long-Term Pain Outcomes

Because corticosteroid injections often deliver rapid short-term relief that fades over time, researchers have increasingly examined whether ESWT maintains superior pain control at longer follow-up intervals. A 2026 meta-analysis of 1,324 participants with chronic plantar fasciitis found ESWT achieved markedly lower pain scores than corticosteroid injection at 6–12 months (p<0.001). This distinction is particularly relevant because many chronic tendon conditions involve altered tendon structure and tissue degeneration rather than ongoing classic inflammation alone, meaning short-term suppression of symptoms may fail to address the underlying problem.

Key long-term findings include:

ESWT produced a standardized mean difference of −0.81 in pain reduction at six months compared with corticosteroid injection, confirming clinically meaningful superiority.
Functional restoration scores consistently favored ESWT, with an SMD of 0.67 for improved foot function at mid-term follow-up.
Recurrence rates remained lower with ESWT, reinforcing its durability as a treatment for chronic, degenerative tendinopathy.

These results position ESWT as the stronger long-term analgesic intervention over corticosteroid injection. Rather than simply masking symptoms, shockwave therapy stimulates neovascularization and collagen production, promoting genuine tissue repair that accounts for its sustained pain relief advantage. Both treatments, however, should be paired with exercise rehabilitation to address loading tolerance, strength, and movement pattern deficits that contribute to tendon dysfunction.

Avoiding Corticosteroid Risks

Given that corticosteroid injections carry well-documented risks of tendon rupture, soft-tissue atrophy, and osseous damage, ESWT’s mechanical mechanism offers a fundamentally safer risk profile for treating chronic tendinopathy.

Meta-analyses report tendon rupture rates of 3–8% in load-bearing tendons after corticosteroid injection, with ruptures occurring as early as two days postinjection. Corticosteroids also cause skin hypopigmentation, fat atrophy, and accelerated joint destruction with repeated use.

ESWT produces no tendon ruptures at recommended settings and generates only transient side effects—localized pain, redness, and bruising. While systematic reviews note adverse events in 26% of ESWT recipients, these remain mild and self-limiting, with no serious complications reported.

ESWT also avoids the systemic risks corticosteroids pose, including osteonecrosis and subchondral fractures, making it a structurally protective alternative.

Side Effects of Shock Wave Therapy for Tendons

Most patients experience some degree of local pain and tenderness at the treatment site during and shortly after ESWT sessions. Systematic reviews show an overall adverse event rate of 26% in ESWT groups compared to 7% in placebo groups, though most effects remain mild and self-limiting.

Common side effects include:

Skin erythema and bruising — redness appears in nearly all treated patients, while petechiae and superficial hematomas typically resolve within one week.
Transient numbness or paraesthesia — temporary nerve irritation near the treatment zone can cause tingling or altered sensation between sessions.
Tendon rupture — although very rare, Achilles tendon ruptures have occurred within two weeks of focused ESWT, particularly in women over 60, underscoring the importance of careful patient screening and post-treatment activity modification.

Why Long-Term Shock Wave Therapy Data Is Still Missing

Although shock wave therapy has accumulated a substantial body of short-term trial evidence for tendinopathies, researchers still lack reliable data on what happens to treated tendons beyond the first year. Most randomized trials report outcomes at three to twelve months, with very few extending past that window.

The limited long-term data that does exist sends mixed signals: Achilles tendinopathy studies show durable relief in some cases, while gluteal tendinopathy success rates drop markedly over time, and rotator cuff cohorts show meaningful surgical conversion rates at four years. One retrospective study assessing ESWT for MRI-confirmed gluteal tendinopathy found that pain scores at a mean 27 months follow-up tended to increase compared to immediate post-treatment levels, reinforcing that initial improvements may not hold.

Compounding this gap, recent meta-analyses rate overall evidence certainty as low or very low for most outcomes. Heterogeneous protocols, small sample sizes, and inconsistent results across tendon sites make long-term extrapolation unreliable. Multi-year trials with standardized designs remain a critical unmet need.

Frequently Asked Questions

How Many Shock Wave Therapy Sessions Are Typically Needed for Tendon Conditions?

Most tendon conditions typically require 3–6 shock wave therapy sessions, spaced about one week apart. Clinicians may extend treatment to 8–10 sessions for chronic or severe tendinopathy that doesn’t respond quickly.

Can Shock Wave Therapy Cause a Tendon to Rupture?

Tendon rupture remains a rare but documented risk, occurring almost exclusively in tendons already weakened by chronic degeneration. Case reports describe Achilles and patellar ruptures days to weeks after treatment, particularly when doses exceed safe thresholds.

Is Shock Wave Therapy Fda-Approved for Treating Tendon Problems?

Like a narrow beam rather than a wide floodlight, FDA approval covers only specific conditions—primarily chronic plantar fasciitis and lateral epicondylitis—not all tendon problems. Most other tendon applications remain off-label or investigational.

Does Shock Wave Therapy Work if Tendon Symptoms Lasted Over a Year?

Research shows shock wave therapy provides minimal additional benefit for tendon symptoms lasting over a year. Meta-analyses haven’t found clinically meaningful improvements beyond what structured rehabilitation programs already offer for long-standing cases.

Can Shock Wave Therapy Eliminate the Need for Tendon Surgery?

ESWT doesn’t reliably eliminate the need for tendon surgery, but it helps a substantial number of patients delay or avoid it—particularly for mid-portion Achilles tendinopathy—when clinicians combine it with tendon loading programmes.

Conclusion

Shock wave therapy doesn’t just nudge chronic tendons toward healing—it practically drags them back from the dead. By triggering microtrauma, sprouting new blood vessels, and resetting haywire pain signals, it reboots a stalled recovery process that’s been stuck for months. When clinicians pair it with targeted loading exercises, the results can feel almost miraculous. It’s not a magic bullet, but for stubborn tendons, it’s arguably the next best thing.

What Does Shock Wave Therapy Do for Tendons?

Key Takeaways

How Shock Wave Therapy Triggers Tendon Healing